A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Syndesi Therapeutics, a Belgium-based developer of therapies to treat cognitive impairment, was acquired by pharmaceutical firm AbbVie yesterday for $130m upfront, with the potential for up to $870m in milestones. The agreement provided an exit to Vives Louvain Technology Fund, the university venture fund of Université Catholique de Louvain, and V-Bio Ventures, the venture capital…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Talking Tech Transfer interview podcast and responsible for the monthly GUV Gazette (sign up here for free).